MyBlueDotsBioSkryb Genomics Launches ResolveSEQ MRD: A Next-Generation Measurable Residual Disease (MRD) Discovery Solution MyBlueDots1 week ago01 mins DURHAM, N.C.–(BUSINESS WIRE)–BioSkryb launches ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of MRD cells. Post navigation Previous: Instem Introduces Cloud-Hosted Non-GLP Pathology Module for ProvantisNext: RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement
Powered by machine learning, a new blood test can enable early detection of multiple cancers MyBlueDots4 days ago 0